Check Cap (CHEK) Hits New 12-Month High and Low at $3.58

Shares of Check Cap Ltd (NASDAQ:CHEK) hit a new 52-week high and low during trading on Thursday . The stock traded as low as $3.58 and last traded at $3.91, with a volume of 101114 shares traded. The stock had previously closed at $5.20.

CHEK has been the subject of several recent analyst reports. HC Wainwright raised their target price on Check Cap from $5.50 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research raised Check Cap from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research report on Monday, January 15th. Finally, ValuEngine raised Check Cap from a “sell” rating to a “hold” rating in a research report on Wednesday.

How to Become a New Pot Stock Millionaire

Check Cap (NASDAQ:CHEK) last released its quarterly earnings data on Wednesday, April 4th. The medical research company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($1.07). research analysts anticipate that Check Cap Ltd will post -6.48 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Check Cap stock. Armistice Capital LLC acquired a new stake in shares of Check Cap Ltd (NASDAQ:CHEK) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 748,000 shares of the medical research company’s stock, valued at approximately $651,000. Armistice Capital LLC owned about 3.88% of Check Cap at the end of the most recent quarter. 22.18% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Check Cap (CHEK) Hits New 12-Month High and Low at $3.58” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3337538/check-cap-chek-hits-new-12-month-high-and-low-at-3-58.html.

Check Cap Company Profile

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing.

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reata Pharmaceuticals  Raised to “Sell” at BidaskClub
Reata Pharmaceuticals Raised to “Sell” at BidaskClub
Territorial Bancorp  Stock Rating Lowered by BidaskClub
Territorial Bancorp Stock Rating Lowered by BidaskClub
VSE  Upgraded at BidaskClub
VSE Upgraded at BidaskClub
Credit Suisse Group Raises Snap  Price Target to $21.00
Credit Suisse Group Raises Snap Price Target to $21.00
Zacks Investment Research Lowers NVR  to Sell
Zacks Investment Research Lowers NVR to Sell
Bristol-Myers Squibb’s  Hold Rating Reiterated at Cowen
Bristol-Myers Squibb’s Hold Rating Reiterated at Cowen


© 2006-2018 Ticker Report. Google+.